MannKind Corporation
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MannKind Corporation is a biopharmaceutical company primarily engaged in the development and commercialization of therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its main products and services include the manufacture and sale of Afrezza, a rapid-acting inhalable insulin for diabetes management; advanced proprietary technologies such as the Technosphere platform for drug delivery; and development of product candidates for respiratory and other systemic diseases. MannKind offers pharmaceutical formulations, delivery devices, and licensing of its inhalation technology platforms. The company operates mainly in the United States but has strategic partnerships allowing its products and technologies to reach broader markets internationally. Founded in 1991 and headquartered in Valencia, California, MannKind continues to focus on innovation in pulmonary drug delivery systems and diabetes treatment solutions. Recent major company developments include strategic partnerships aimed at expanding the commercialization and distribution of Afrezza, along with ongoing research collaborations to enhance its proprietary Technosphere platform. Over the last one to two years, MannKind has also pursued product pipeline expansions and has announced progress in clinical trials targeting pulmonary and systemic diseases beyond diabetes. The company has not undergone any name changes or major reorganizations but has actively refined its operational focus to strengthen its market position within the biopharmaceutical industry. MannKind's business segments include pharmaceutical product development and manufacturing, technology licensing, and strategic alliances. Its target customers encompass healthcare providers, patients with chronic diseases such as diabetes, and biotechnology collaborators. The company operates as an independent publicly traded entity under the ticker symbol MNKD. It manages subsidiaries related to product development and technology commercialization to support its core operations.
Company News
MannKind to Present at Upcoming Investor Conferences
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
MannKind: New Approvals Majorly Increase MannKind's Prospects
MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
MannKind Q2 Earnings Call Highlights
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics
MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript
MannKind's Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway
MannKind injection helps heart failure patients avoid ER infusions
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
MannKind (NASDAQ:MNKD) Shares Gap Up – Still a Buy?
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE
MannKind Announces $50 Million Private Placement
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
What This MannKind Filing Reveals About Three Years of Underperformance